Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A

Overview

The purpose of this study is to develop oral controlled release formulation of Huperzine A that will provide optimal pharmacokinetic profile of the drug enhancing safety and compliance, as possible cure to neurodegenerative disorders.

Full Title of Study: “An Open-label, Three-period, Crossover Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Different Release Rate Controlled Release Formulations of Huperzine A (0.4mg)Compared to the Equivalent Dose of an Immediate Release Formulation.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2011

Interventions

  • Drug: Huperzine A
    • Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.

Arms, Groups and Cohorts

  • Active Comparator: IR formulation
    • Healthy volunteers will receive imediate release formulation of Huperzine A (0.4mg)
  • Experimental: CR 1
    • CR formulation Healthy volunteers will receive controlled release formulation 1 of Huperzine A (0.4mg)
  • Experimental: CR 2
    • CR formulation Same volunteers will receive controlled release formulation 2 of Huperzine A (0.4mg)

Clinical Trial Outcome Measures

Primary Measures

  • Pharmacokinetic parameters of Huperzine A different formulations
    • Time Frame: Blood samples will be taken for 36 hours after Huperzine A administration
    • Pharmacokinetic parameters: C max, T max, AUC, t1/2

Secondary Measures

  • Laboratory testing of peripheral AchE inhibition by Huperzine A. Evaluation of adverse events. Laboratory testing of peripheral AchE inhibition by Huperzine A. Evaluation of adverse events.
    • Time Frame: 36 hours

Participating in This Clinical Trial

Inclusion Criteria

1. Healthy males between the age of 18 and 35, inclusive (ASA = 1) 2. Body weight > 50 kg 3. Subject has a BMI less than 27 and more than 20 4. Participants should be able to ingest oral medication 5. The ability to understand and sign a written informed consent form, prior to participation and the willingness to comply with all study requirements Exclusion Criteria:

1. History of drug sensitivity or drug allergy 2. History of sensitivity to eggs 3. Subject has a BMI less than 20 and more than 27 4. Previous participation in an investigational trial involving administration of any investigational compound within 1 month prior to the current study 5. History of alcoholism or drug addiction 6. Any medication taken including over-the-counter medications and herbal products within 14 days of commencing study drug dosing with the exception of vitamins and/or paracetamol. When a concomitant medication is necessary, this will be reviewed by the investigator and if not contraindicated, may be continued at the same dose and frequency during the study period 7. History of clinically important illness (ASA>1); Disorders or conditions that could affect the absorption, distribution, metabolism and/or excretion of drugs (e.g. malabsorption, edema, renal or hepatic insufficiency) 8. Inability to relate to and/or cooperate with the investigators 9. Blood loss or donation greater than 200ml in the 3 months prior to the trial 10. Exhausting physical exercise during the previous 48 hours to drug administration 11. Subjects who have smoked or used nicotine-containing products within 6 months prior to study entry

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Hadassah Medical Organization
  • Collaborator
    • Hebrew University of Jerusalem
  • Provider of Information About this Clinical Study
    • Eliad Davidson, MD, School of pharmacy, Hebrew University of Jerusalem
  • Overall Official(s)
    • Michael Friedman, Proffesor, Principal Investigator, Institute for Drug Research, Hebrew University of Jerusalem, Israel
  • Overall Contact(s)
    • Gregory Burshtein, MA, 97226758665/4, bursht@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.